文献速递湿疹皮炎与荨麻疹自身免疫性与大疱性皮肤病

低水平NLRP3嵌合体在慢性荨麻疹样皮损中的作用

Low-level NLRP3 mosaicism in chronic urticarial lesions: extending the phenotypic spectrum of NLRP3-related disorders and therapeutic implications.
PubMed 文献 · Br J Dermatol · 2025-01-01

研究对4例曾诊断为新生儿NUD、Schnitzler综合征、HUVS或巨细胞动脉炎的非瘙痒性慢性荨麻疹样皮损患者行常规及高深度NGS,发现2例常规NGS检出NLRP3嵌合体(VAF 5%和11%),另2例高深度NGS检出VAF低至2-3%;所有变异均激活NF-κB通路,抗IL-1治疗均改善症状。

要点

  • 慢性荨麻疹样皮损早发或晚发、孤立或模拟其他疾病均需考虑NLRP3嵌合体。
  • 常规NGS可漏检低水平嵌合体,高深度NGS(>1500×)有助检出VAF低至2-3%的变异。
  • 确诊NLRP3相关疾病可及时启动抗IL-1治疗,预防系统性淀粉样变性等并发症。

核心结论

  • NLRP3嵌合体是慢性荨麻疹样皮损的潜在病理机制,无论早发或晚发、孤立或模拟其他疾病。
  • 即使极低水平白细胞嵌合体也可致病,因血液含NLRP3炎症小体激活的关键靶细胞。
  • 高深度NGS诊断NLRP3相关疾病可及时启动抗IL-1治疗,对预防系统性淀粉样变性等并发症至关重要。

研究设计与样本

  • 研究纳入4例无亲缘关系、初始诊断为新生儿NUD、Schnitzler综合征、HUVS或巨细胞动脉炎的患者。
  • 对白细胞DNA行常规NGS,并补充高深度NGS(>1500×)以提高SAID相关基因低水平嵌合体检出。
  • 对重组NLRP3蛋白行功能试验,评估所鉴定变异对NF-κB通路的影响。

主要发现

  • 1例自出生起持续孤立性荨麻疹样皮损,另3例为晚发性皮肤病变。
  • 2例常规NGS检出NLRP3嵌合体,VAF分别为5%和11%。
  • 另2例高深度NGS检出NLRP3嵌合体,VAF低至2-3%。
  • 所有鉴定变异均激活NF-κB通路,显示功能获得效应。
  • 后续抗IL-1治疗使所有患者症状改善。

临床怎么用

  • 对慢性荨麻疹样皮损,尤其非瘙痒性、早发或晚发、孤立或模拟其他疾病者,应考虑NLRP3嵌合体检测。
  • 常规NGS阴性时,可采用高深度NGS(>1500×)检测低水平嵌合体。
  • 确诊NLRP3相关疾病后应及时启动抗IL-1治疗,以改善症状并预防系统性淀粉样变性等并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic urticarial lesions, a common condition of mostly unknown cause, can occur in immune dysregulation disorders such as hypocomplementaemic urticarial vasculitis syndrome (HUVS), neutrophilic urticarial dermatosis (NUD) and systemic autoinflammatory diseases (SAIDs), including Schnitzler syndrome. OBJECTIVES: To identify the molecular basis of nonpruritic chronic urticarial eruptions in four unrelated patients initially diagnosed with neonatal NUD, Schnitzler syndrome, HUVS or giant-cell arteritis. METHODS: Conventional next-generation sequencing (NGS) of leucocyte DNA was supplemented with high-depth NGS (> 1500×) to improve the detection of low-level mosaicism in SAID-related genes. Functional assays were performed on recombinant NLRP3 proteins to assess the impact of the identified variations on the nuclear factor-κB (NF-κB) pathway. RESULTS: One patient presented with persistent isolated urticarial lesions since birth, while the other three experienced late-onset skin lesions. In contrast to the initially suspected diagnoses, conventional NGS revealed NLRP3 mosaicism in two patients, with variant allele fractions (VAFs) of 5% and 11%, respectively. In the other two patients, high-depth NGS uncovered NLRP3 mosaicism with VAFs as low as 2-3%. All identified variations activated the NF-κB pathway, demonstrating a gain-of-function effect. Subsequent anti-interleukin-1 therapy led to symptom improvement for all patients. CONCLUSIONS: This study highlights the importance of considering NLRP3 mosaicism as an underlying pathological mechanism in chronic urticarial lesions, whether of early or late onset, and whether isolated or mimicking other conditions. As blood contains key target cells for NLRP3 inflammasome activation, even extremely low-level leucocyte mosaicism can be pathogenic. High-depth NGS-based diagnosis of NLRP3-related disorders enables timely initiation of anti-IL-1 therapy, which is crucial to preventing complications such as systemic amyloidosis. Urticaria is a common illness. It affects up to 1 in 5 people at some point in their lives. Urticaria causes very itchy, raised skin reactions called ‘hives’. When urticaria lasts for 6 weeks or more, it is called chronic urticaria. Often, the cause of chronic urticarial lesions is unknown. In some cases, it may be linked to problems with the immune system. We studied four patients with unexplained chronic urticarial lesions. Each of them showed symptoms that looked like different types of inflammatory diseases. Using genetic techniques, we analysed DNA from blood samples taken from the patients. We found genetic changes in a gene called ‘NLRP3’, which plays an important role in controlling inflammation. These changes were found in only a small number of the patients’ cells but were enough to cause symptoms. The age when the disease started was different for each patient – from early infancy to over 60 years old. The patients’ symptoms also changed over time. Some signs of inflammation and results from skin biopsies were different depending on how active the disease was. Our study suggests that early- and late-onset chronic urticaria could be caused by disorders involving the ‘NLRP3’ gene. Genetic tests are important to make the right diagnosis. This helps doctors avoid mistakes and choose the best treatment. Early treatment with a drug that blocks a protein called ‘IL-1’ may help prevent serious long-term problems, such as a condition called amyloidosis, a condition that can lead to kidney failure.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Daskalopoulou A, Assrawi E, Diab F, et al. Low-level NLRP3 mosaicism in chronic urticarial lesions: extending the phenotypic spectrum of NLRP3-related disorders and therapeutic implications. Br J Dermatol. 2025. PMID: 40493737. doi:10.1093/bjd/ljaf220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。